Eli Lilly logo

Eli Lilly

LLY | NYSE
Chart Builder DCF Calculator
$1,434.26
-$9.24 (-0.64%)
At close: Nov 16, 2026, 3:59 PM ET
$1,436.00
+$1.74 (+0.12%)
After-hours: Nov 16, 2026, 7:59 PM ET
-0.64%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
80
-0.1 pts
Fundamentals Excellent
Market Sentiment Bullish
Moat Wide
Sector Rank #22/1021 (Top 2%)

Why Price Moved

17 days ago
+3.19%

Shares are trading higher after the company report...

Key Statistics

Market Data

Market Cap $1.35T
1D Range
1,427.66 1,475.25
52W Range
851.21 1,475.25

Valuation (TTM)

PE 46.55
PB 33.50
EV/EBITDA 31.44

Valuation (NTM)

Forward PE 40.81
Forward PEG 0.94
Price Target $1,440.00
Loading financial charts...

Profile

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a c...

Sector Healthcare
Employees 50,000
IPO Date Jun 1, 1972
Fiscal Year January - December

Latest News

Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody

12 hours ago · gurufocus.com

Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody
Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

13 hours ago · wsj.com

Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

15 hours ago · zacks.com

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027

1 day ago · fool.com

Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
Mapping the Market: Eli Lilly shares ready to rally again

3 days ago · reuters.com

Mapping the Market: Eli Lilly shares ready to rally again
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020

4 days ago · prnewswire.com

Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It

4 days ago · fool.com

Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
China approves Eli Lilly's weight loss pill orforglipron

4 days ago · reuters.com

China approves Eli Lilly's weight loss pill orforglipron
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

5 days ago · benzinga.com

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

5 days ago · prnewswire.com

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Earnings

Latest Earnings
Oct 29, 2026
EPS
$7.48
Beat +31.00%
REV
$24.4B
Beat +8.03%
Next Earnings
Feb 3, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
22
Consensus
Buy
Price Target
$1,440.00
Upside
+0.40%
Buy (21)
Hold (0)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.